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Endocytosis of the Mu Opioid Receptor
Reduces Tolerance and a Cellular Hallmark
of Opiate Withdrawal
cytosed into an intracellular compartment from which
they can be recycled to the membrane (resensitization)
or targeted for degradation leading to receptor down-
regulation. These processes can contribute directly to
tolerance by decreasing the number of functional cell
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University of California, San Francisco surface receptors. However, morphine-activated MORs
Emeryville, California 94608 elude GRK phosphorylation and subsequent arrestin
binding and desensitization (Blake et al., 1997; Whistler
and von Zastrow, 1998; Zhang et al., 1998). Additionally,
morphine fails to promote endocytosis of the wild-type
Summary (WT) MOR in cultured cells (Arden et al., 1995; Keith et
al., 1996) and native neurons (Sternini et al., 1996; Keith
Morphine is unusual in its failure to promote robust et al., 1998), whereas endogenous endorphin peptide
desensitization and endocytosis of the mu opioid re- ligands and other opiate drugs such as methadone readily
ceptor (MOR), processes that for many receptors con- drive receptor endocytosis (Sternini et al., 1996; Keith
tribute directly to tolerance. This apparent paradox et al., 1998; Trapaidze et al., 2000). Hence it is unlikely
has led us to revise the idea that receptor desensitiza- that tolerance and withdrawal to morphine are mediated
tion and endocytosis are solely responsible for toler- solely by desensitization and downregulation of the re-
ance and withdrawal to morphine, and instead test ceptor.
the hypothesis that these side effects occur due to We have previously shown that replacing the cyto-
abnormally prolonged MOR signaling. We report here plasmic tail of the MOR with the cytoplasmic tail of the
that MOR mutations that facilitate endocytosis reduce delta opioid receptor (DOR) is sufficient to confer a gain-
the development of cellular tolerance and cAMP super- of-function phenotype in which morphine can induce
activation, a cellular hallmark of withdrawal. Moreover, GRK phosphorylation, arrestin recruitment and subse-
mutant receptors with reduced endocytosis produce quent endocytosis of the receptor (Whistler et al., 1999).
exacerbated superactivation. These data demonstrate Furthermore, the ability of an agonist to promote endo-
a critical role for receptor endocytosis in the develop- cytosis of the MOR is not linearly related with agonist
ment of adverse side effects associated with pro- activity, indicating that MOR endocytosis is an indepen-
longed opiate use. dent functional property. Since agonist activity and re-
ceptor endocytosis have opposing effects on receptor
mediated signaling, the net amount of signal transmitted
Introduction
to the cell is a function of both processes, a relationship
we term RA/VE, for relative activity versus endocytosis.
Although morphine is one of the most effective drugs
Thus, morphine would have a particularly high RA/VE
commonly used for treating pain, its therapeutic utility
value due to its inability to promote receptor desensitiza-
is limited in many people by the development of both
tion and endocytosis (Whistler et al., 1999). Endorphins
tolerance (reduced responsiveness to the same dose of
and opiate drugs of less abuse potential that acutely
drug), and withdrawal (an adverse physiological reaction signal with similar efficacy yet induce receptor desensiti-
following removal of drug) (De Quincey, 1822). Abuse of zation and endocytosis would have lower RA/VE values
morphine and its derivatives remains a controversial than morphine. These observations have led us to pro-
social issue, imparting considerable economic and per- pose that drugs with high RA/VE values, such as mor-
sonal costs to society (Burroughs, 1953). Morphine ex- phine, have an enhanced propensity to produce the
erts its effects through the mu opioid receptor (MOR) adverse effects associated with prolonged drug expo-
(Matthes et al., 1996), a Gi/o-coupled member of the hepta- sure precisely because they signal through the receptor
helical family of plasma membrane receptors (Evans, for aberrantly long periods of time. It follows that if pro-
1993). Despite considerable progress, the molecular and longed signaling at the MOR is contributing to the devel-
cellular mechanisms mediating the development of tol- opment of tolerance and withdrawal, then molecular
erance and withdrawal to morphine remain controversial events that reduced this prolonged signaling, such as
(Nestler, 1996, 2001; Williams et al., 2001). desensitization and endocytosis, would reduce the de-
Signaling from many G protein coupled receptors velopment of these side effects.
(GPCRs) is regulated by a well-characterized and highly Chronic morphine treatment of cells in culture
conserved mechanism involving receptor phosphoryla- (Sharma et al., 1975; Avidor-Reiss et al., 1996) and ani-
tion by G protein coupled receptor kinase (GRK) and mals (Bonci and Williams, 1997; Chieng and Williams,
subsequent arrestin recruitment (Ferguson, 2001). These 1998) produces a compensatory upregulation of the cAMP
processes can contribute directly to GPCR desensitiza- pathway, an effect that has been studied as a cellular
tion by facilitating the uncoupling of receptor from G hallmark of opiate withdrawal. We hypothesize that cAMP
protein. Following desensitization, receptors are endo- superactivation results from aberrantly prolonged sig-
naling through the MOR because of its failure to undergo
desensitization and endocytosis. This aberrantly pro-3 Correspondence: shooz2@itsa.ucsf.edu
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longed inhibition of adenylyl cyclase would produce the readily drives endocytosis of WT MOR, morphine fails
to promote appreciable endocytosis (compare Figure 1,previously observed adaptive cellular changes underly-
ing cAMP superactivation (Nestler, 1996; Williams et al., A–B, left two panels). However, D MOR and R MOR are
readily endocytosed following activation with morphine2001). To test this hypothesis, we measured cAMP su-
peractivation in cells expressing wild-type and mutant (Figure 1, C–D, left two panels). Postendocytic trafficking
of the mutant receptors was also assessed by an immu-versions of the MOR with altered endocytic and posten-
docytic properties. Because the compensatory changes nofluorescence assay. Cells stably expressing WT MOR,
D MOR, and R MOR were given antibody and treatedassociated with cAMP superactivation are postulated
to lead to long lasting changes in gene expression, we with agonist. Residual surface antibody was stripped
from receptors and cells returned to media containingmeasured both cAMP and the expression of a cAMP-
Response-Element (CRE)-driven luciferase reporter gene the MOR antagonist naloxone to block subsequent en-
docytosis. Consistent with previous studies (Whistler etto assess superactivation at the level of altered gene
expression. al., submitted), endocytosed WT MOR reappeared on
the plasma membrane following a burst of endocytosis,We report here that cells expressing mutant versions
of the MOR that undergo morphine-induced endocyto- demonstrating that it was recycled (Figure 1B). D MOR
failed to show appreciable reappearance of plasmasis show reduced cellular tolerance and reduced cAMP
membrane staining, demonstrating that these receptorssuperactivation following chronic morphine treatment
were not efficiently recycled (Figure 1C). However, Rcompared to wild-type MOR expressing cells. Further-
MOR showed a reappearance of staining on the plasmamore, the development of cellular tolerance and cAMP
membrane similar to that of WT MOR, indicating that itsuperactivation in wild-type MOR expressing cells was
was recycled following endocytosis (Figure 1D).not accompanied by receptor desensitization. Finally,
We next assessed downregulation of these receptorswhereas wild-type MOR expressing cells chronically
using radioligand binding. These data indicated atreated with methadone demonstrate less superactiva-
greater than 50% reduction in binding sites in D MORtion compared to cells chronically treated with mor-
following 2.5 hr of morphine treatment, whereas analo-phine, cells expressing mutant receptors that fail to
gously treated WT MOR and R MOR showed no signifi-undergo methadone induced endocytosis show exacer-
cant reduction in binding sites (Figure 1E). Since radioli-bated methadone-mediated superactivation. These data
gand binding does not selectively measure the behaviordemonstrate a critical role for prolonged signaling and
of endocytosed receptors, we also used a modified ver-MOR endocytosis in the development of physiological
sion of a previously described (Whistler et al., 1999)responses associated with tolerance and withdrawal.
biotin protection assay to selectively observe the endo-
cytic properties and the postendocytic fate of internal-
Results ized receptors. For these experiments, cells were biotin-
ylated and treated with agonist for either 30 min to
Altered Endocytosis and Post-Endocytic assess rapid endocytosis or 2.5 hr in the continued pres-
Trafficking of MOR Mutants ence of agonist to assess stability. The WT MOR showed
The cytoplasmic tail of the wild-type murine MOR1 (WT agonist-specific endocytosis (Figure 1F, compare lanes
MOR) was replaced with various portions of the cyto- 4 and 5) and D MOR and R MOR showed robust endocy-
plasmic tail of the DOR, and these receptors were stably tosis following activation with morphine (Figure 1, G–H,
transfected into HEK 293 cells. D MOR is identical to compare lanes 3 and 5). The endocytosed pool of WT
the previously reported MOR-DOR chimera, in which MOR remained relatively stable (Figure 1F, compare
the entire cytoplasmic tail of the MOR has been replaced lanes 4 and 7). To confirm that the endocytosed recep-
by the cytoplasmic tail of the DOR (Whistler and von tors were recycled, cells were incubated in agonist for
Zastrow, 1999). R MOR is a variant of this receptor in 30 min and then with the antagonist naloxone for 2 hr
which residues 386–398 of the primary splice variant of to block subsequent receptor endocytosis. Remaining
the MOR, MOR1, are intact. It has been shown pre- biotin-labeled receptors on the plasma membrane were
viously that the postendocytic fate of the DOR is differ- then stripped. WT MOR expressing cells treated in this
ent from that of other heptahelical receptors (Tsao and way showed very little internalized, protected receptor
von Zastrow, 2000). Following their endocytosis, DORs (Figure 1F, compare lanes 7 and 8), demonstrating that
are targeted for degradation in lysosomes by a specific the endocytosed receptors were efficiently recycled to
sorting operation. Replacing the cytoplasmic tail of the the plasma membrane during the 2 hr treatment with
MOR with that of the DOR altered not only the ability of antagonist. D MOR showed a substantial loss in the
the receptor to endocytose with morphine, but also its endocytosed pool of receptors following 2.5 hr of contin-
postendocytic fate (Whistler et al., submitted), confer- ued agonist (Figure 1G, compare lane 4 to 7, and com-
ring the DOR degradative fate on the chimeric receptor. pare lane 5 to 9), indicating that endocytosed D MOR
The R MOR receptor was generated to produce a mutant degraded, consistent with previous studies (Whistler et
MOR that would endocytose with morphine and recycle al., in preparation). Like WT MOR treated with DAMGO, R
to the plasma membrane. MOR remained relatively stable following 2.5 hr agonist
The endocytic and postendocytic behavior of these treatment compared to 30 min (Figure 1H, compare lane
mutants was assessed first by a previously described 4 to 7 and lane 5 to 9), indicating the relative stability
antibody feeding experiment using different opioid li- of these internalized receptors. Furthermore, R MOR
gands (Whistler and von Zastrow, 1998; Tsao and von expressing cells treated with agonist followed by antag-
onist showed very little internalized protected receptorZastrow, 2000). Whereas the enkephalin analog DAMGO
Endocytosis Reduces Tolerance and Withdrawal
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Figure 1. Altered Endocytosis and Post-Endocytic Trafficking in MOR Mutants
(A–D) Immunocytochemical time course of cells labeled with M1 antibody directed to the N-terminal FLAG tag of WT MOR (A and B), D MOR
(C), and R MOR (D). Following treatment with agonist (5 M, 30 min) to induce the endocytosis of a pulse of M1-labeled receptors, remaining
surface receptors were stripped of antibody, antagonist naloxone was added (10 M) to prevent further endocytosis, and the reappearance
of M1-bound receptor returning to the plasma membrane was observed over a time course. Representative results of two independent
experiments shown. (E) Radioligand binding of 3H diprenorphine assessed following 2.5 hr morphine (5 M), expressed as the percent inhibition
of maximal binding in matched untreated controls, means  SEM of three independent experiments performed in quadruplicate, p  0.001
D MOR treated versus untreated, one-way analysis of variance (1  ANOVA), with Tukey posttest. (F–H) Biotin protection assay in which drug
treatment for specified time was followed by strip of remaining plasma membrane receptors and remaining internalized protected receptor
pool visualized by SDS-PAGE with streptavidin overlay. A representative result of at least three independent experiments shown in (F–H) and
quantified in (I) (1  ANOVAs, with Tukey posttests: Morphine-induced endocytosis of mutant receptors, p  0.05 R MOR and D MOR versus
WT MOR Morphine 30 min; postendocytic stability of mutant receptors, p  0.05 D MOR DAMGO 2 hr 30 min versus WT MOR and R MOR
DAMGO 2 hr 30 min, p  0.001 R MOR Morphine 2 hr 30 min versus D MOR Morphine 2 hr 30 min; stable receptors recycle, p  0.001 WT
MOR DAMGO 2 hr 30 min versus DAMGO 30 min/Naloxone (Nx) 2 hr, R MOR DAMGO 2 hr 30 min versus DAMGO 30 min/Nx 2 hr, R MOR
Morphine 2 hr 30 min versus Morphine 30 min/Nx 2 hr).
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(Figure 1H, compare lane 7 to 8 and 9 to 10), indicating only in its ability to undergo morphine-induced endocy-
tosis, showed significantly attenuated superactivationthat the endocytosed receptor was recycled. Hence, we
have generated three different MORs, each with distinct of the cAMP pathway as assessed by measurement of
whole-cell cAMP (Figure 2C, green bar). Furthermore, Dtrafficking properties: WT MOR does not endocytose
with morphine and recycles following DAMGO-induced MOR showed a complete absence of cAMP superactiva-
tion (Figure 2C, black bar). We attribute the completeendocytosis; D MOR endocytoses with morphine and
is degraded; R MOR endocytoses with morphine and is loss of superactivation in D MOR to both a reduction of
aberrantly prolonged signaling, as well as the loss ofrecycled.
cell surface receptors due to downregulation (Figures
1C, 1E, and 1G). Most importantly, these same trends
Endocytosis of the MOR Reduces Superactivation in superactivation were observed at the level of changes
of the cAMP Pathway in CRE-luciferase expression (Figure 2, D–E) demon-
With these tools, we investigated whether alterations strating that alterations in the endocytic properties of
in receptor endocytosis that alter the RA/VE value of the MOR could affect changes in gene expression asso-
morphine would alter superactivation of the cAMP path- ciated with prolonged drug treatment. The reduced
way. Double stably transfected HEK 293 cells containing cAMP superactivation of D MOR and R MOR is not likely
both a wild-type or mutant MOR and a CRE-luciferase due to alterations in acute signaling capacity of these
reporter gene were treated chronically with morphine mutant receptors, since acute inhibition of forskolin-
and superactivation of the cAMP pathway was as- stimulated CRE-luciferase expression did not differ sig-
sessed. Consistent with numerous other studies in cell nificantly between WT MOR, D MOR, and R MOR at all
culture and animals, chronic morphine treatment of cells agonist doses tested (Figure 2F), nor are they different in
expressing WT MOR resulted in a compensatory upreg- their ability to acutely inhibit forskolin-stimulated whole-
ulation of the cAMP pathway as assessed by measure- cell cAMP (data not shown).
ment of whole-cell cAMP (Figure 2A). Importantly, when The reduced cAMP superactivation of R MOR and D
CRE-driven luciferase expression was measured in MOR suggests that endocytosis is sufficient to prevent
these same cells, chronic morphine treatment also pro- the development of compensatory adaptive cellular
duced a robust increase in luciferase gene expression changes associated with opiate withdrawal. Therefore,
(Figure 2B), indicating that superactivation of this path- it would be predicted that chronic treatment of WT MOR
way occurred not only at the level of cAMP but also at expressing cells with opiate ligands that promote endo-
the level of gene expression. Furthermore, consistent cytosis should also produce reduced cAMP superacti-
with the hypothesis that prolonged signaling through vation. Indeed, chronic treatment of WT MOR express-
the Gi/o-coupled MOR produces superactivation of the ing cells with the morphine analog methadone, a drug
cAMP pathway, pretreatment of WT MOR cells with per- that drives endocytosis of WT MOR (Trapaidze et al.,
tussis toxin (PTX) completely blocked superactivation 2000) (Figure 3A), produced significantly less cAMP su-
of CRE-luciferase expression (Figure 2B). peractivation than did morphine as assessed at the level
Previous studies have demonstrated that activation of CRE-luciferase expression (Figure 2G) and whole-
of CRE-mediated gene expression requires not only ac- cell cAMP (Figure 3B). The attenuated CRE-luciferase
tivation of PKA but also activation of mitogen-activated superactivation of methadone relative to morphine is
protein kinase (MAPK) (Impey et al., 1998; Pierce et al., not due to reduced ability of methadone to signal per
2001). Furthermore it has been reported that endocyto- se, since methadone was as potent as morphine in its
sis of some receptors is required for efficient MAPK ability to acutely inhibit forskolin-stimulated CRE-lucif-
activation to occur (Daaka et al., 1998), although endocy- erase expression in these cells (Figure 2H).
tosis does not appear to be required for opioid receptor
mediated signaling to MAPK (Whistler and von Zastrow,
1999). Nevertheless, it was possible that superactiva- Reduced Endocytosis Exacerbates Superactivation
of the cAMP Pathwaytion, as assessed by CRE-mediated gene expression,
was reflecting differences in MAPK signaling rather than Since manipulations of the MOR that increased its endo-
cytosis reduced the development of cAMP superactiva-PKA signaling. To assess this possibility, cells were
treated chronically with morphine in the presence of tion, we conversely predicted that mutations that inhib-
ited endocytosis would exacerbate superactivation. Tothe MAPK inhibitor PD 98059. Cells treated in this way
showed superactivation of CRE-luciferase reporter ex- examine this, we introduced alanine mutations into the
four most distal hydroxylated amino acids of thepression at levels similar to that of cells not treated with
inhibitor (Figure 2B). Similar results were also obtained in C-terminal tail of the MOR, generating a loss of function
phenotype whereby methadone failed to induce GRKthe presence of the PKC inhibitor chelerythrine chloride
(Figure 2B). These results suggest that superactivation phosphorylation, arrestin recruitment (data not shown),
and endocytosis of the receptor (Figure 3A). Stablyof CRE-luciferase expression is not mediated by alter-
ation of either MAPK or PKC signaling and thus it is likely transfected HEK 293 cells expressing this mutant ala-
nated MOR, A MOR, were chronically treated with meth-to accurately reflect, at the level of gene expression,
superactivation of the cAMP pathway. adone and whole-cell cAMP superactivation measured.
As predicted, a significant increase in cAMP superacti-Next, we directly addressed the RA/VE hypothesis
by determining if cells expressing R MOR and D MOR vation was observed in these cells compared to analo-
gously treated WT MOR expressing cells (Figure 3B).showed reduced cAMP superactivation following chronic
morphine treatment. R MOR, which differs from WT MOR Thus, a mutation that reduced receptor endocytosis
Endocytosis Reduces Tolerance and Withdrawal
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Figure 2. Reduction of cAMP Superactivation by Mu Opioid Receptor Endocytosis
Data presented as mean  SEM of at least three independent experiments performed in triplicate. (A) Superactivation of cAMP pathway
assessed by 125I radioimmunoassay (RIA) during withdrawal following 14 hr (chronic) 1M morphine, p 0.0001 paired t test. (B) Superactivation
of CRE-luciferase expression measured following chronic 1 M morphine treatment was blocked by PTX (100 ng/ml 12 hr pretreatment), 1 
ANOVA, Tukey posttest p  0.001, and unaffected by cotreatment with the MAP kinase inhibitor PD 98059 (PD-10 M), or the protein kinase
C inhibitor chelerythrine chloride (CC-10 M). (C) cAMP superactivation measured following chronic 1 M morphine treatment, comparing
mutant opioid receptors, 1  ANOVA, Tukey posttests p  0.05 R MOR versus WT MOR, p  0.001 D MOR versus WT MOR, p  0.001 D
MOR versus R MOR, D MOR showed no significant superactivation. (D) CRE-luciferase superactivation measured following chronic 1 M
morphine treatment, comparing mutant opioid receptors, 1  ANOVA, Tukey posttests p  0.001 R MOR versus WT MOR, p  0.001 D MOR
versus WT MOR, p  0.01 D MOR versus R MOR, D MOR showed no significant superactivation. (E) Dose-response curves comparing CRE-
luciferase superactivation following chronic morphine, 2  ANOVA, Bonferroni posttests, R MOR versus WT MOR p  0.001 at 100 nM and
1 M, D MOR versus WT MOR p  0.001 at 10 nM, 100 nM, and 1 M, D MOR versus R MOR p  0.05 at 1 nM and p  0.001 at 10 nM, 100
nM, and 1 M, D MOR showed no significant superactivation. (F) Dose response curve of acute ability of morphine to inhibit forskolin-
stimulated (2 M) CRE-luciferase expression, assessed 4 hr following concurrent application of drugs, 2  ANOVA, Bonferroni posttests p 
0.05. (G) Dose response curve of CRE-luciferase expression following chronic morphine (dashed line) versus methadone (solid line) treatment
of WT MOR expressing cells, 2  ANOVA, Bonferroni posttests p  0.001 at 100 nM and 1 M. (H) Dose-response curve of acute ability of
morphine (dashed line) versus methadone (solid line) to inhibit forskolin-stimulated (2 M) CRE-luciferase expression, assessed 4 hr following
concurrent application of drugs, 2  ANOVA, Bonferroni posttests p  0.05.
conferred a gain-of-function phenotype in which chronic superactivation is not likely to reflect intrinsic cAMP
mediated signaling differences between A MOR and WTmethadone treatment resulted in exacerbated superac-
tivation. This difference in methadone-induced cAMP MOR, since both exhibited similar acute opiate-induced
Neuron
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sion (Figures 2B, 2E, and 2G), we predicted that CRE-
luciferase expression would be elevated in the chroni-
cally treated cells following morphine rechallenge when
compared to naive cells. As expected, in WT MOR ex-
pressing cells, the level of CRE-luciferase expression in
response to an acute dose of morphine was significantly
higher in chronically treated cells than in naive cells
(Figure 4A, compare bars 2 and 4, p  0.01). This is a
decreased physiological response (here, an increase in
the amount of CRE-luciferase expressed) to the same
dose of drug, and hence demonstrates that the cells
had become tolerant. This cellular tolerance is a direct
consequence of the superactivation that has altered the
baseline levels of cAMP in the cell (Figure 4A, compare
bars 1 and 2 to bars 3 and 4). Because the cellular
tolerance in WT MOR expressing cells was a conse-
quence of cAMP superactivation, we predicted that re-
ducing superactivation would reduce cellular tolerance.
As expected, cells expressing R MOR demonstrated
significantly less cellular tolerance following chronic
morphine treatment than did cells expressing WT MOR
(Figure 4A, compare bars 4 and 5, p  0.01). This re-
duced cellular tolerance in R MOR cells is readily attrib-
uted to the decreased superactivation observed in these
cells during withdrawal (compare bars 3 and 4 to bars
Figure 3. Reduced Endocytosis Exacerbates cAMP Superacti- 6 and 5).
vation A further analysis of the data in Figure 4 examines the
(A) Cells expressing FLAG-tagged A MOR were compared to WT role of receptor desensitization and downregulation in
MOR expressing cells in their ability to undergo methadone-induced tolerance. Following chronic morphine treatment, WT
endocytosis. (B) cAMP superactivation assessed during withdrawal MOR expressing cells were tolerant (Figure 4A, compare
to chronic 10 nM morphine or 10 nM methadone by RIA. Data are
lanes 2 and 4), but the receptors in these cells were notpresented as mean  SEM of three independent experiments per-
desensitized. This was demonstrated by the fact thatformed in triplicate, paired t test, p  0.05 WT MOR versus A MOR
the fold inhibition produced by morphine rechallenge offollowing chronic methadone.
chronically treated cells was not significantly different
from the fold inhibition produced by morphine treatment
of naive cells (Figure 4A, compare bars 1 and 2 to bars
inhibition of whole-cell cAMP (data not shown). Because 3 and 4, and Figure 4B for quantitation). Hence, the
A MOR expressing cells treated with methadone still WT MOR cells were tolerant despite the absence of
showed reduced superactivation compared to WT MOR significant receptor desensitization. The R MOR cells
cells treated with morphine, further analysis of the sig- that showed reduced tolerance (Figure 4A, compare
naling properties of A MOR may be necessary to fully bars 4 and 5) also demonstrated no significant receptor
explain these differences in cAMP superactivation. desensitization (Figure 4A, compare bars 8 and 7 to bars
6 and 5, and Figure 4B for quantitation). Thus, consistent
Tolerance Due to Receptor Desensitization with the failure of the WT MOR to endocytose and the
Is Dissociable from Tolerance Due ability of R MOR to recycle following its endocytosis,
to Elevated cAMP Baseline these results indicate that the receptors in these WT
We next examined whether mutations that affected mor- MOR and R MOR expressing cells had not become de-
phine-induced endocytosis of the receptor altered the sensitized during chronic morphine treatment.
development of tolerance to morphine. While tolerance Classically, receptor endocytosis has been thought
can be broadly defined as a decreased physiological to contribute directly to tolerance by decreasing the
response to the same dose of drug (Snyder, 1996), there number of G protein coupled receptors on the cell sur-
are several cellular mechanisms which might contribute. face through the processes of desensitization and down-
In order to dissociate tolerance that occurred as a con- regulation. Consistent with this notion, the fold inhibi-
sequence of an elevated cAMP baseline (superactiva- tion produced by morphine rechallenge of chronically
tion) from tolerance that occurred due to desensitization treated D MOR expressing cells is significantly attenu-
and downregulation of receptors, a morphine rechal- ated relative to the fold inhibition produced by morphine
lenge experiment was performed. In this rechallenge treatment of naive D MOR cells (Figure 4B, compare
experiment, CRE-luciferase expression resulting from bars 9 and 10 to bars 11 and 12, and see Figure 4B for
an acute dose of morphine was compared between cells quantitation). We attribute the loss of signaling capacity
chronically treated with morphine, and cells not chroni- in D MOR expressing cells to receptor downregulation
cally treated with morphine (“naive cells”). Because the as a result of arrestin-mediated desensitization, endocy-
superactivation resulting from chronic morphine treat- tosis, (Whistler et al., 1999) and subsequent degradation
(see Figures 1C, 1E, and 1G) (Whistler et al., submitted).ment elevated the baseline of CRE-luciferase expres-
Endocytosis Reduces Tolerance and Withdrawal
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Figure 4. Tolerance Due to Receptor Desen-
sitization Is Dissociable from Tolerance Due
to Elevated cAMP Baseline
(A) For this rechallenge experiment, CRE-
luciferase expression resulting from an acute
dose of morphine was compared between
cells chronically treated with morphine and
cells not chronically treated with morphine
(naive cells). Cells were treated chronically
with morphine (1 M, 14 hr) or left untreated.
A withdrawal phase was then initiated by
three washes, followed by a 4 hr acute phase
in the presence or absence of morphine (1
M), and CRE-luciferase expression mea-
sured. CRE-luciferase expression in un-
treated, morphine naive cells was defined as
100. The level of CRE-luciferase expression
was significantly higher in the chronically
treated WT MOR cells receiving a morphine
rechallenge than in the naive WT MOR cells
that received a single dose of acute morphine
(compare bars 2 and 4, p 0.01, 1 ANOVA,
Tukey posttest), demonstrating that the cells
had become tolerant to the effects of mor-
phine. This tolerance was reduced in analo-
gously treated R MOR cells (compare bars 4
and 5, p 0.01, 1 ANOVA, Tukey posttest),
as a direct result of R MOR’s attenuated su-
peractivation (compare bars 3 and 6) (red
barsWT MOR, green bars R MOR, black
bars  D MOR). (B) Quantitation of the fold
inhibition shown in (A). For both WT MOR
cells and R MOR cells, the fold inhibition of
forskolin-stimulated CRE-luciferase produced by acute morphine in chronically treated cells was not significantly different from the fold
inhibition of forskolin-stimulated CRE-luciferase in naive cells. In contrast, the fold inhibition of forskolin-stimulated CRE-luciferase produced
by acute morphine in chronically treated D MOR cells was significantly decreased compared to the fold inhibition of forskolin-stimulated CRE-
luciferase in naive D MOR cells, 1  ANOVA, Tukey posttest, p  0.001.
Thus, we have shown with D MOR that receptor de- Here we dissociate two different mechanisms under-
lying tolerance: tolerance due to desensitization andsensitization and endocytosis can be a first step toward
receptor downregulation, and can indeed contribute di- downregulation of receptors (D MOR, and see black
trace on model Figure 5), and tolerance due to elevatedrectly to tolerance by reducing overall receptor number.
However, we have also demonstrated with WT MOR that baseline levels of cAMP (WT MOR, and see red trace
on model Figure 5). In the constant presence of drug,cellular tolerance can occur in the absence of receptor
desensitization. Furthermore, we have shown with R these two forms of tolerance would be indistinguishable
(compare red and black trace at point B on model inMOR that this cellular tolerance can be reduced by mu-
tations that enhance endocytosis of a recycling recep- Figure 5). However these two mechanisms of achieving
tolerance can readily be distinguished by assessing re-tor. Therefore, in contrast to the prevailing hypothesis
that enhanced endocytosis contributes directly to in- sponsiveness to a rechallenge of drug. If receptors have
become desensitized, then rechallenge with drug willcreased tolerance, we have demonstrated with R MOR
that enhancing endocytosis actually reduced the devel- produce a reduced response (black trace Figure 5 at
point D, and D MOR in Figure 4). However, if receptorsopment of cellular tolerance.
In summary, cells expressing WT MOR show signifi- are not desensitized, rechallenge will produce a fold
inhibition similar to that achieved in naive cells (WT MORcant cAMP superactivation (withdrawal) and cellular tol-
erance as a direct consequence of superactivation. Cells in Figure 4; red trace in model Figure 5, compare red
dashed lines).expressing R MOR show reduced withdrawal and con-
sequently reduced cellular tolerance. Cells expressing
D MOR do not show withdrawal but show profound
Discussiontolerance due to receptor desensitization and downreg-
ulation. Hence, the postendocytic fate of a GPCR
Consistent with the RA/VE model, chronic treatment ofstrongly influences the role that endocytosis plays in the
cells expressing R MOR produced significantly reduceddevelopment of tolerance (Figure 5). For the recycling
cAMP superactivation, an effect we attribute to endocy-receptor, endocytosis reduced tolerance by reducing
tosis of the receptor and the consequent abrogation ofcAMP superactivation; for the degrading receptor, en-
prolonged signaling to the cell. Furthermore, methadone,docytosis contributed directly to the development of
a drug that promotes receptor endocytosis, producedtolerance by facilitating post-endocytic downregulation
of the receptor. significantly less superactivation than did morphine on
Neuron
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Figure 5. Model of cAMP Responsiveness in
Cells Treated Chronically with Morphine
Gray bar represents an idealized situation, in
which cells respond robustly to morphine (A)
and retain equivalent responsiveness as long
as drug is present (B, gray bar). When drug
is withdrawn, cAMP returns to the same
baseline as in naive cells (C, gray bar). In the
idealized situation, reapplication of drug (2)
leads to equivalent inhibition as naive cells
(D, gray bar). Development of tolerance, red
and black bar: Cells treated chronically with
morphine show reduced responsiveness to
drug following chronic treatment (B, red and
black bar). Black bar represents cells that
have become tolerant to morphine because
of loss of receptors due to receptor desensiti-
zation and downregulation. In this situation,
removal of the drug would return cells to the
baseline cAMP levels observed in naive cells
(C, black bar), since residual receptor medi-
ated signaling would be removed. Reapplica-
tion of drug (2) to these preexposed cells
would give reduced responsiveness com-
pared to naive cells because of receptor de-
sensitization and downregulation (D, black
bar). The black bar approximates our observations with cells expressing D MOR. Red bar represents cells that have become tolerant to
morphine because of compensatory cellular changes in signaling through the cAMP pathway. Upon removal of drug, cells show superactivated
baseline levels of cAMP compared to naive cells (C, red bar). Removal of morphine, and hence removal of chronic receptor-mediated inhibition,
reveals these cellular compensatory changes. In these superactivated cells, reapplication of drug produces cAMP inhibition of the same
magnitude as naive cells (see red dashed bars), but because the baseline cAMP levels have changed, the absolute response is diminished
(compare A and D, red bar). This superactivation is a cellular hallmark of withdrawal, and is demonstrated with the WT MOR data. At points
B and D, when drug is present, the tolerance observed due to cellular compensation (red bar), and receptor desensitization and downregulation
(black bar) are indistinguishable. Tolerance due to cellular compensatory changes is only revealed upon removal of drug. Green bar represents
reduced cellular tolerance (point B and D versus point A, green bar) and reduced withdrawal (point C) because of reduced compensatory
cellular changes (R MOR data).
WT MOR expressing cells. Importantly, methadone pro- tors that appear tolerant to morphine since morphine
would no longer seem to be inhibiting the cAMP-signal-duced increased superactivation in cells expressing the
A MOR mutant receptor that did not endocytose. Hence, ing cascade to the same degree as it did acutely. How-
ever, we and others have shown that morphine-acti-we have shown that facilitating morphine-induced endo-
cytosis can attenuate the development of a cellular vated receptors remain functionally coupled to cyclase
inhibition even after chronic morphine treatment (Figurehallmark of opiate withdrawal, whereas blocking endo-
cytosis in response to methadone can exacerbate the 4) (Blake et al., 1997; Zhang et al., 1998; Whistler and
von Zastrow, 1998). Withdrawal of morphine relievesdevelopment of this adverse side effect of long-term
drug exposure. While the cAMP superactivation observed this inhibition and consequently unmasks the superacti-
vation of the cAMP pathway produced by the cellularin WT MOR cells was accompanied by cellular tolerance,
receptor desensitization did not occur. Furthermore, the adaptive changes. In short, we view these compensa-
tory changes as a form of cellular tolerance that is mostreduced cAMP superactivation achieved through recep-
tor endocytosis in R MOR resulted in reduced cellular clearly revealed upon withdrawal of the drug, and is
distinguishable from tolerance mediated by receptor de-tolerance.
Several groups have reported superactivation of the sensitization and downregulation (Figure 4 and see
model, Figure 5, compare black and red traces).cAMP-signaling pathway in response to chronic morphine
treatment in brain regions implicated in addiction, includ- In transfected CHO cells, other groups have reported
DAMGO to be three times as potent as morphine ating the locus coeruleus (Nestler, 1996), ventral tegmental
area (Bonci and Williams, 1997), and nucleus accumbens inducing cAMP superactivation following chronic treat-
ment, despite the enhanced endocytosis induced by(Chieng and Williams, 1998). Cellular changes occurring
during cAMP superactivation include increased expres- DAMGO. This observation is nonetheless consistent
with the RA/VE model since in these cells DAMGO is 24sion of certain adenylyl cyclases, PKA, and CREB (Wil-
liams et al., 2001; Nestler, 2001). These adaptive cellular times more potent than morphine at acutely inhibiting
forskolin-induced cAMP production (Avidor-Reiss et al.,changes would be predicted to compensate for contin-
ued inhibition of adenylyl cyclase, and are functionally 1995). Correcting for potency, these data indicate
DAMGO to be eight times less potent than morphine atanalogous since they serve to increase the amount of
signaling through the cAMP pathway following pro- inducing cAMP superactivation, a difference we attri-
bute to these drugs’ varying ability to induce receptorlonged inhibition by morphine. Importantly, any of these
compensatory changes could produce cells with recep- endocytosis. The intriguing recent observation that
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10% Fetal Bovine Serum (Hyclone). Mu opioid receptor and CRE-chronic opioid treatment also leads to constitutive acti-
Luciferase (Promega) constructs were stably transfected using cal-vation of MOR suggests the possibility that adaptive
cium phosphate co-precipitation, with single colonies chosen andchanges other than superactivation may also be modu-
propagated in the presence of selection-containing media. For im-
lated by receptor endocytosis (Liu and Prather, 2001). munocytochemistry, cells were grown on poly-lysine coated cov-
Withdrawal from methadone often produces a severe erslips and incubated with 3.5 g/ml M1 anti-FLAG (Covance) anti-
withdrawal syndrome (Burroughs, 1956), an observation body for 30 min. Cells were then treated with 5 M agonist as
that ostensibly contradicts our finding that methadone specified, fixed in 4% formaldehyde in PBS, permeabilized in
0.1%Triton X-100, and stained with Cy3-conjugated Donkey anti-produces less cAMP superactivation compared to mor-
Mouse antibody (Jackson Immunoresearch). Images were acquiredphine (Figure 2G). However, it is important to note that
using a custom-configured inverted microscope (Prairie Systems,methadone replacement is primarily given to addicts
Madison, WI) with a Zeiss 63  oil objective. For recycling experi-with considerable histories of prior opiate use (typically
ments, M1 anti-FLAG treated cells were exposed to ligand, followed
morphine and heroin), thus raising the likelihood that by a brief 5 min rinse in 37C PBS/EDTA to preferentially disrupt
compensatory changes have already occurred in these the extracellular calcium-sensitive M1-epitope interaction. Warmed
patients prior to methadone administration. Hence, dur- naloxone (10 M)-containing media was then added to the cells and
samples fixed and stained as described above at specified timeing withdrawal from methadone, it is difficult to dissoci-
points.ate effects due to methadone from the effects resulting
from prior morphine and heroin use. Clinical data exam-
Biotin Protection Assayining this issue would be of interest, but difficult to
Cells were grown to 80% confluency in 10 cm plates, washed withacquire, given the paucity of a morphine-naive, metha-
PBS, and then treated with 3 g/ml disulfide-cleavable biotindone-experienced subject pool, and the ethical dilem-
(Pierce) in PBS at 4C for 30 min. Cells were then washed in PBS
mas associated with performing well-controlled studies and placed in prewarmed media for 15 min, prior to treatment with
to examine this relationship. specified ligands for varying periods of time. Concurrent with ligand
The observation that -arrestin 2 knockout mice show treatment, 100% and strip plates remained at 4C. Following ligand
reduced analgesic tolerance (Bohn et al., 2000) suggests treatment, plates were washed in PBS, and remaining cell surface
biotinylated receptors stripped in 50 mM glutathione, 0.3 M NaCl,that in certain cell types MOR signaling can be desensi-
75 mM NaOH, and 1% fetal bovine serum at 4C for 30 min for alltized by -arrestin 2. Interestingly, these mutant mice
ligand-treated plates as well as strip plate. Cells were extracted instill demonstrate withdrawal from morphine, as assessed
0.1% Triton X-100, 150 mM NaCl, 25 mM KCl, and 10 mM Tris HCl,biochemically with cAMP superactivation as well as be-
pH 7.4, and cellular debris removed by centrifugation at 10,000  g
haviorally, suggesting that even in cases where receptor for 10 min at 4C. Lysates were immunoprecipitated with anti-FLAG
desensitization by -arrestin may be contributing to tol- M2 (Covance), rabbit anti-mouse linker antibody (Jackson Immuno-
erance, withdrawal is a dissociable phenomenon. Nev- research), and Protein A sepharose (Pharmacia) overnight. Immuno-
precipitates were washed 5 and incubated with PNGase F (NEB)ertheless, a clear interpretation of these data is difficult
for 2 hr. Samples were then denatured in SDS sample buffer withgiven the incomplete assessment of tolerance and su-
no reducing agent and resolved by SDS/PAGE, transferred to nitro-peractivation in the mouse brain, where an emerging
cellulose, biotinylated proteins exposed to Vectastain ABC immu-picture of regional differences in the extent of chronic
noperoxidase reagent (Vector Laboratories), developed with ECL
morphine-induced MOR desensitization (Sim et al., reagents (Amersham), visualized on a Storm 860 (Molecular Dynam-
1996; Sim-Selley et al., 2000) as well as regionally distrib- ics), and quantified with ImageQuant 5.0.
uted splice variants differing in their cytoplasmic tails
(Abbadie et al., 2000) promises to impart considerable Whole-Cell Cyclic AMP
complexity to the biochemical characterization of these Radioimmunoassay by 125I cAMP (NEN) was used. For chronic drug
experiments, 14 hr of drug was followed by a withdrawal phaseprocesses in different brain regions.
introduced by washing the cells once in DMEM/FBS, followed by aUsing a well-characterized cell culture model, we have
PBS rinse, followed by 15 min incubation in 5 mM IBMX to inhibitshown that a cellular hallmark of withdrawal, cAMP su-
phosphodiesterases. Cells were then treated with 2 M forskolinperactivation, is ameliorated by receptor mutations that
for 10 min, and harvested as prescribed (NEN). Acute signaling
facilitate receptor endocytosis and exacerbated by mu- experiments were performed analogously, except that cells were
tations that block endocytosis. Based on these data, it treated for 3 min with 2 M forskolin and opiate drug, a time at
would be predicted that mice harboring targeted inser- which significant endocytosis did not occur (data not shown).
tions of R MOR would show reduced withdrawal behav-
iorally, and less cAMP superactivation biochemically. It Radioligand Binding
would also be predicted that prolonged clinical expo- 3H Diprenorphine (2 nM) was added to cells in Krebs-Ringer Hepes
buffer in presence or absence of 10 M cold naloxone for 30 min.sure to novel opiate analogs that promote endocytosis
Following collection of cells by vacuum filtration through glass fiberof the MOR would produce ameliorated withdrawal com-
filters (Packard Instruments) and 17 washes with cold Tris-bufferedpared to morphine when given at equieffective analgesic
saline, pH 7.4, remaining radioactivity was counted. Bound countsdoses. Hence, our data suggest a revision of the prevail-
represented 10% of input radioligand. Nonspecific binding, de-
ing hypothesis that receptor desensitization and endo- fined by assays conducted in the presence of 10 M cold naloxone,
cytosis contribute directly to the development of opiate was 10% of total counts isolated on filters. Using this procedure,
tolerance and withdrawal and instead suggest that these at least two cell lines were selected for each construct, all having
levels of expression from 2–7 pmole/mg protein.processes are essential for homeostatic regulation of
important signaling cascades.
CRE-Luciferase Reporter Expression Assays
Cells were grown to confluency in 24-well plates. For acute treat-Experimental Procedures
ment experiments, cells were given drug for 4 hr and the fold inhibi-
tion of forskolin-stimulated luciferase activity measured. For chronicCell Culture and Immunocytochemistry
treatment experiments, cells were given drug for 14 hr, rinsed threeHuman Embryonic Kidney (HEK) 293 cells (American Type Culture
Collection) were grown in DMEM (Gibco BRL) supplemented with times in drug free media to initiate a withdrawal phase, then given
Neuron
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2 M forskolin for the 4 hr withdrawal phase, and luciferase activity De Quincey, T. (1822). Confessions of an English Opium Eater. (Lon-
don: Taylor and Hessey).measured. For rechallenge experiments, cells were given drug for
14 hr, rinsed three times in drug free media to initiate a withdrawal Evans, C.J. (1993). Diversity Among the Opioid Receptors. In Biologi-
phase, and 1 M morphine was then given concurrently with for- cal Basis of Substance Abuse, S.G. Korenman, and J. D. Barchas,
skolin during the 4 hr withdrawal phase. 14 hr was chosen after an eds. (New York: Oxford University Press), pp. 31–48.
initial time course of superactivation in mu expressing HEK 293 cells
Ferguson, S.S. (2001). Evolving concepts in G protein-coupled re-
demonstrated that superactivation at this time point was highly
ceptor endocytosis: the role in receptor desensitization and signal-
reproducible. For cells in all treatment conditions, cells were rinsed
ing. Pharmacol. Rev. 53, 1–24.
once in PBS immediately prior to luciferase measurement. 100 l
Impey, S., Obrietan, K., Wong, S.T., Poser, S., Yano, S., Wayman,Cell Culture Lysis Reagent (Promega) was added to each well, a 20
G., Deloulme, J.C., Chan, G., and Storm, D.R. (1998). Cross talkl cell lysate aliquot was transferred to an opaque 96-well plate,
between ERK and PKA is required for Ca2	 stimulation of CREB-100l substrate added per well using a Lucy 2 luminometer (Anthos),
dependent transcription and ERK nuclear translocation. Neuron 21,and light measurements collected. Data were exported to Microsoft
869–883.Excel for compilation, and GraphPad Prism 3.0 for graphical display,
nonlinear regression curve fitting, and subsequent statistical Keith, D.E., Anton, B., Murray, S.R., Zaki, P.A., Chu, P.C., Lissin, D.V.,
analyses. Monteillet-Agius, G., Stewart, P.L., Evans, C.J., and von Zastrow,
M. (1998). mu-Opioid receptor internalization: opiate drugs have
differential effects on a conserved endocytic mechanism in vitro
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